Dark Forest Capital Management LP Makes New Investment in Haemonetics Co. (NYSE:HAE)

Dark Forest Capital Management LP purchased a new position in Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 4,720 shares of the medical instruments supplier's stock, valued at approximately $369,000.

Several other hedge funds and other institutional investors have also made changes to their positions in HAE. TD Waterhouse Canada Inc. purchased a new stake in Haemonetics during the fourth quarter valued at $25,000. Covestor Ltd raised its position in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after buying an additional 439 shares in the last quarter. Whittier Trust Co. bought a new position in shares of Haemonetics in the 4th quarter valued at about $62,000. Parkside Financial Bank & Trust grew its position in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares in the last quarter. Finally, AlphaQuest LLC grew its position in Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after acquiring an additional 1,826 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HAE. Raymond James restated a "strong-buy" rating and set a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price target for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Barrington Research reduced their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, JMP Securities dropped their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $101.22.

Haemonetics Trading Up 1.5 %

Shares of NYSE HAE traded up $0.95 during trading hours on Friday, reaching $63.94. The stock had a trading volume of 534,756 shares, compared to its average volume of 691,967. The business's fifty day moving average price is $62.73 and its two-hundred day moving average price is $71.72. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of 25.17, a P/E/G ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a 52-week low of $55.30 and a 52-week high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.